CMS granted the reimbursement for cervical fusion procedures using the company’s Aprevo personalized interbody implants. Approval comes as part of the centers’ Hospital Inpatient Prospective Payment Systems Final Rule (IPPS) for fiscal year (FY) 2026.

NTAP provides additional reimbursement to hospitals that use designated new medical technologies in the first few years of market introduction. Starting Oct. 1, cervical fusion procedures utilizing Aprevo devices are eligible for additional payment from CMS and private payors. This provides up to an additional $21,125 in reimbursement for qualifying procedures.

Carlsbad, California–based Carlsmed designed the Aprevo devices to match the unique anatomical and alignment needs of each patient. The company’s proprietary AI-powered surgical planning platform and digital production system power the devices.